History

Survodutide (BI 456906) was co-invented by Zealand Pharma and Boehringer Ingelheim, which licensed it and now leads global development. Discovery and preclinical pharmacology were published in Molecular Metabolism in 2022. Phase 2 trials enrolled from 2021, with results published across 2023-2024 in Diabetologia, The Lancet Diabetes & Endocrinology, and the New England Journal of Medicine. The FDA granted Breakthrough Therapy designation for MASH in October 2024, and Phase 3 programs began the same year. The first Phase 3 obesity trial, SYNCHRONIZE-1, reported positive topline results in April 2026.

Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3 topline readout. But as of June 2026 it is not approved anywhere, and its Phase 3 data have not yet been peer-reviewed.

What it is

Survodutide is a once-weekly subcutaneous peptide, structurally a modified 29-amino-acid glucagon analog (molecular formula C₁₉₂H₂₈₉N₄₇O₆₁; CAS 2805997-46-8). It is engineered for stability and a long half-life: a non-standard amino acid at position 2 resists enzymatic breakdown, the C-terminus is amidated, and a C18 fatty-diacid chain lets it bind albumin and circulate for days.

Pharmacologically it is a dual agonist — it activates both the GLP-1 receptor and the glucagon receptor. Measured at human receptors in cell assays, the two potencies are roughly balanced (GLP-1 receptor EC₅₀ around 0.33 nM, glucagon receptor around 0.52 nM). At likely therapeutic exposure, though, the drug fully switches on the GLP-1 receptor but only partially activates the glucagon receptor, so its real-world behavior is GLP-1-weighted.

The rationale: GLP-1 activation curbs appetite and slows gastric emptying, while glucagon activation is thought to add increased energy expenditure and direct effects on the liver. The glucagon arm is deliberately kept partial, because glucagon signaling can in theory raise blood glucose. It is developed by Boehringer Ingelheim and remains experimental.

The claims

Because survodutide is not marketed, the only way consumers encounter it is through “research chemical” vendors who sell it labeled “for research use only, not for human consumption.” Marketing around it tends to frame it as a next-generation fat-loss and liver drug you can obtain now, sometimes citing the trial weight-loss figures as if they applied to whatever is in the vial. Both the efficacy framing and the availability framing need scrutiny.

The evidence

The human data are real and, by gray-market standards, unusually solid. Three separate randomized, double-blind, placebo-controlled Phase 2 trials have been published, all funded by the developer, Boehringer Ingelheim.

In a 46-week Phase 2 obesity dose-finding trial (le Roux et al., Lancet Diabetes & Endocrinology, 2024) in 386 treated adults with a BMI of 27 or higher and no diabetes, mean weight loss reached about 14.9% at the top dose versus 2.8% on placebo. Side effects were common, however: 91% of survodutide recipients reported an adverse event (75% gastrointestinal), and 25% discontinued because of side effects, versus 4% on placebo.

In a 48-week Phase 2 MASH trial (Sanyal et al., New England Journal of Medicine, 2024) in adults with biopsy-confirmed disease and fibrosis (295 enrolled per the trial registry; 293 analyzed in the publication), the primary endpoint — improvement in MASH on biopsy without worsening fibrosis — was met in 47%, 62%, and 43% across the three doses, versus 14% on placebo. Liver-fat reduction of at least 30% occurred in roughly 57–63% on drug versus 14% on placebo.

In a 16-week Phase 2 type 2 diabetes trial (Blüher, Rosenstock et al., Diabetologia, 2024) in 411 treated adults on metformin, with an open-label semaglutide reference arm, survodutide produced an HbA1c reduction up to about 1.71% and weight loss up to about 8.7% (8.4 kg), versus 5.3% (5.2 kg) on semaglutide. Again, tolerability was a limiting factor: 77.8% of survodutide recipients had an adverse event versus about 52% on semaglutide or placebo, with 15.9% discontinuing for side effects.

In April 2026, the developer announced positive topline results from the first Phase 3 trial, SYNCHRONIZE-1 (obesity, 76 weeks): up to 16.6% weight loss versus 3.2% on placebo, with 85.1% of participants losing at least 5% of body weight versus 38.8% on placebo. Both co-primary endpoints were met.

The important caveats are why this stays at “Preliminary human” rather than “Strong human.” The Phase 3 result exists only as a company press release — it has not been peer-reviewed or published (full data are slated for a June 2026 conference), and every other indication remains at Phase 2. All published efficacy data come from the manufacturer, with company employees as authors and co-inventors, which is a genuine conflict-of-interest flag. Published durations are short (16–48 weeks), and there are no long-term safety, durability, or hard-outcome data (cardiovascular events, cirrhosis progression). There is no independent, non-sponsor replication yet. The MASH Phase 3 program (LIVERAGE) has not read out.

Safety and side effects

In trials the dominant problem was gastrointestinal — nausea, vomiting, diarrhea, and constipation — dose-dependent and the leading cause of dropout. As noted above, discontinuation for side effects ran around 16% in diabetes and 25% in obesity at effective doses. A post-hoc analysis of the obesity trial reported improvements in blood pressure.

Beyond what the trials measured, glucagon-receptor activation can raise heart rate and, in theory, glucose, and the broader GLP-1 drug class carries label-level concerns including gallbladder events, a pancreatitis signal still under study, and a rodent thyroid-tumor signal of uncertain human relevance. Long-term human safety for survodutide specifically is not established. And none of the trial safety data apply to unregulated gray-market product, which carries additional, unquantified risks — independent testing of online peptides broadly finds under-dosing, contamination, and wrong sequences. Nothing here is medical advice.

Legal and regulatory status

Survodutide is not approved by the FDA or any other regulator, for any use, as of June 2026. In October 2024 the FDA granted it Breakthrough Therapy designation for non-cirrhotic MASH with moderate-to-advanced fibrosis; that designation only speeds review and is not an approval or proof of efficacy. Phase 3 programs are ongoing in obesity (SYNCHRONIZE, with SYNCHRONIZE-1 reporting positive topline in April 2026 and a cardiovascular-outcomes study attached) and in MASH (LIVERAGE).

Because it is not marketed, any product sold as “survodutide” is unapproved and unregulated, sidestepping FDA oversight and GMP, purity, and sterility requirements. There is no quality assurance for any consumer-obtained material.

For athletes: survodutide is not specifically named on WADA’s 2026 Prohibited List, and the GLP-1 class is not banned — semaglutide and tirzepatide are on WADA’s 2026 Monitoring Program (watched for possible misuse), not prohibited, though a future ban is reportedly under consideration. However, as an unapproved investigational substance, survodutide could fall under WADA category S0, which prohibits any pharmacological agent not approved by any health authority for human use. Any competing athlete should treat its status as unsettled and confirm with their anti-doping authority directly.

Bottom line

Survodutide has a real, well-designed human evidence base — three placebo-controlled Phase 2 trials and one positive Phase 3 topline — that puts it well ahead of typical gray-market peptides. But it is still experimental: the Phase 3 data are not yet peer-reviewed, the evidence is entirely sponsor-funded and short-term, and the drug is not approved or legally available anywhere. Tolerability, driven by gastrointestinal side effects, is a recurring limitation. Anything sold online today is unapproved and unverified.

Survodutide: Strong Phase 2 data and a first Phase 3 readout, but still investigational